Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

IDENTIFICATION OF RAT AND HUMAN CYTOCHROME P450 FORMS INVOLVED IN THE METABOLISM OF THE THROMBOXANE A2 RECEPTOR ANTAGONIST (+)-S-145

Yoshitaka Yamaguchi, Shirou Kirita, Takahiko Baba, Junko Aoyama, Akira Touchi, Robert H. Tukey, F. Peter Guengerich and Takashi Matsubara
Drug Metabolism and Disposition January 1997, 25 (1) 75-80;
Yoshitaka Yamaguchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shirou Kirita
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takahiko Baba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junko Aoyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akira Touchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert H. Tukey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Peter Guengerich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Matsubara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

(+)-S-145 {5-(+)-(Z)-7-[(1R, 2S, 3S, 4S)-3-phenylsulfonylaminobicyclo[2.2.1]hept-2-yl]-heptenoic acid} and its β-oxidized metabolites {two [bisnor or dihydro (DH)-bisnor] or four (tetranor) carbon-shortened products at the carboxyl side chain} are hydroxylated at the C-5 or C-6 position of the bicyclo ring by microsomal monooxygenases. We investigated the oxidative metabolism of (+)-S-145 and its β-oxidized metabolites with liver microsomes from rats and humans to identify which cytochrome P450 (P450) forms are involved in these reactions. In rats, phenobarbital or dexamethasone treatment significantly increased 5- and 6-hydroxylation activities toward (+)-S-145 and its β-oxidized metabolites, suggesting the involvement of P4503A forms. Immunoinhibition studies suggested that P4503A2 was mainly responsible for the 5-hydroxylation of (+)-S-145, bisnor, and DH-bisnor and the 6-hydroxylation of bisnor and tetranor. Furthermore, P4502C6, a phenobarbital-inducible 2C form in the rat, was involved in the 6-hydroxylation of (+)-S-145, bisnor, and DH-bisnor. P4502C11, the major constitutive form (male rats), was partly involved in the 5-hydroxylation of DH-bisnor and the 6-hydroxylation of bisnor and DH-bisnor. Reconstitution studies with purified human enzymes and immunoinhibition studies suggest that P4503A4 is primarily involved in the 5-hydroxylation of (+)-S-145 and bisnor and the 6-hydroxylation of tetranor; P4502C9/10 mainly catalyzed the 5-hydroxylation of tetranor and the 6-hydroxylation of (+)-S-145. Results of the present study indicated that the same subfamily P450 forms are responsible for the oxidative metabolism of (+)-S-145 in rats and humans. P4503A enzymes were shown to be involved in the formation of 6-hydroxy tetranor, the main metabolite of S-1452 in vivo.

Footnotes

  • Send reprint requests to: Yoshitaka Yamaguchi, Department of Drug Metabolism and Disposition, Developmental Research Laboratories, Shionogi & Co., Ltd., 3-1-1 Futaba-cho, Toyonaka, Osaka 561, Japan.

  • A portion of this study was supported in part by U.S. Public Health Service Grants CA44353, ES00267 (to F.P.G.), and 6H36590 (to R.H.T.).

  • Abbreviations used are::
    (+)-S-145
    5-(+)-(Z)-7-[(1R, 2S, 3S, 4S)-3-phenylsulfonylaminobicyclo[2.2.1]hept-2-yl]-heptenoic acid
    S-1452
    (+)-S-145 calcium dihydrate
    DH-bisnor
    5-[(1R, 2S, 3S, 4S)-3-phenylsulfonylaminobicyclo-[2.2.1]hept-2-yl]-pentanoic acid
    bisnor
    (3Z)-5-[(1R, 2S, 3S, 4S)-3-phenylsulfonylaminobicyclo-[2.2.1]hept-2-yl]-3-pentenoic acid
    tetranor
    3-[(1R, 2S, 3S, 4S)-3-phenylsulfonylaminobicyclo-[2.2.1]hept-2yl]-proionic acid
    OH
    hydroxy
    P450
    cytochrome P450
    PB
    phenobarbital
    DEX
    dexamethasone
    DLPC
    dilauroylphosphatidylcholine
    DOPC
    dioleoylphosphatidylcholine
    PS
    phosphatidylserine
    PC
    phosphatidylcholine
    IgG
    immunoglobulin G
    • Received May 20, 1996.
    • Accepted September 26, 1996.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition
Vol. 25, Issue 1
1 Jan 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
IDENTIFICATION OF RAT AND HUMAN CYTOCHROME P450 FORMS INVOLVED IN THE METABOLISM OF THE THROMBOXANE A2 RECEPTOR ANTAGONIST (+)-S-145
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

IDENTIFICATION OF RAT AND HUMAN CYTOCHROME P450 FORMS INVOLVED IN THE METABOLISM OF THE THROMBOXANE A2 RECEPTOR ANTAGONIST (+)-S-145

Yoshitaka Yamaguchi, Shirou Kirita, Takahiko Baba, Junko Aoyama, Akira Touchi, Robert H. Tukey, F. Peter Guengerich and Takashi Matsubara
Drug Metabolism and Disposition January 1, 1997, 25 (1) 75-80;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

IDENTIFICATION OF RAT AND HUMAN CYTOCHROME P450 FORMS INVOLVED IN THE METABOLISM OF THE THROMBOXANE A2 RECEPTOR ANTAGONIST (+)-S-145

Yoshitaka Yamaguchi, Shirou Kirita, Takahiko Baba, Junko Aoyama, Akira Touchi, Robert H. Tukey, F. Peter Guengerich and Takashi Matsubara
Drug Metabolism and Disposition January 1, 1997, 25 (1) 75-80;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Endogenous substrates of rat organic cation transporters
  • Catabolism and Metabolism of ABBV-011, a Calicheamicin ADC
  • Gadoxetate-enhanced MRI and FXR in benign tumours
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics